Germany’s Medigene AG is getting a new biotech startup going, out-licensing its AAV-like particle tech to the newly minted Swedish biotech company 2A Pharma AB, located in Malmö, Sweden.
Medigene says that it was working on AAV particle tech before devoting itself to T cells and immunotherapy. And now 2A Pharma plans to use it to develop new vaccines, for cancer as well as infectious diseases. And the upstart says it’s raised enough cash to take the biotech up to the clinic, though it did not spell out the details on that score.
Prof. Søren Nielsen is working as CEO, Preben Bruun Nyzell as CFO and Dr. John Nieland as COO of the new company.
“We founded 2A Pharma AB in order to further develop this very interesting AAVLP technology. We are convinced of the future potential of the same as an innovative therapy and we are pleased that we have attracted investors who will provide us sufficient funding to reach the clinical development stage,” noted Nielsen.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,100+ biopharma pros who read Endpoints News by email every day.Free Subscription